The Incidence and Burden of Peripheral Neuropathy in Pediatric Oncology Patients Receiving Levofloxacin and Vincristine Compared With Vincristine Alone
Abstract
Levofloxacin is the first line antibiotic used to prevent infection in pediatric oncology patients with prolonged and profound neutropenia. These patients often receive vincristine, a critical component of therapy for leukemia and for many solid tumors. Both levofloxacin and vincristine are known to cause peripheral neuropathy (PN); however, the cumulative effect of both drugs on PN remains unknown. The objective of this study was to evaluate the incidence and extent of PN in pediatric oncology patients receiving vincristine and levofloxacin (VL) compared with vincristine alone (VA). In this retrospective cohort study, manual chart review was performed to extract demographic and clinical data for newly diagnosed patients treated at our institution between 2015 and 2020. Patients who received vincristine alone (VA) were compared with patients who received vincristine and levofloxacin (VL). There was no significant difference in the incidence of peripheral neuropathy between the 2 groups; however, the cohort exposed to vincristine and levofloxacin (VL) experienced significantly more peripheral neuropathy symptoms, had more affected categories of peripheral neuropathy, and received additional treatment for their neuropathy symptoms. Exposure to levofloxacin in addition to vincristine therapy was associated with an increased burden of peripheral neuropathy in this pediatric oncology cohort.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.